Literature DB >> 16289629

Acetylation and deacetylation of non-histone proteins.

Michele A Glozak1, Nilanjan Sengupta, Xiaohong Zhang, Edward Seto.   

Abstract

Since the first report of p53 as a non-histone target of a histone acetyltransferase (HAT), there has been a rapid proliferation in the description of new non-histone targets of HATs. Of these, transcription factors comprise the largest class of new targets. The substrates for HATs extend to cytoskeletal proteins, molecular chaperones and nuclear import factors. Deacetylation of these non-histone proteins by histone deacetylases (HDACs) opens yet another exciting new field of discovery in the role of the dynamic acetylation and deacetylation on cellular function. This review will focus on these non-histone targets of HATs and HDACs and the consequences of their modification.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16289629     DOI: 10.1016/j.gene.2005.09.010

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  615 in total

Review 1.  The role of epigenetic regulation in stem cell and cancer biology.

Authors:  Lilian E van Vlerken; Elaine M Hurt; Robert E Hollingsworth
Journal:  J Mol Med (Berl)       Date:  2012-06-02       Impact factor: 4.599

2.  Operating on chromatin, a colorful language where context matters.

Authors:  Kathryn E Gardner; C David Allis; Brian D Strahl
Journal:  J Mol Biol       Date:  2011-01-25       Impact factor: 5.469

Review 3.  Histone deacetylase inhibitors as therapeutic agents for acute central nervous system injuries.

Authors:  Na'ama A Shein; Esther Shohami
Journal:  Mol Med       Date:  2011-01-25       Impact factor: 6.354

4.  LBH-589 (panobinostat) potentiates fludarabine anti-leukemic activity through a JNK- and XIAP-dependent mechanism.

Authors:  Roberto Rosato; Stefanie Hock; Paul Dent; Yun Dai; Steven Grant
Journal:  Leuk Res       Date:  2011-11-08       Impact factor: 3.156

5.  Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines.

Authors:  Wei Zhang; Michael Peyton; Yang Xie; Junichi Soh; John D Minna; Adi F Gazdar; Eugene P Frenkel
Journal:  J Thorac Oncol       Date:  2009-02       Impact factor: 15.609

6.  Quantitative Analysis of the Proteome Response to the Histone Deacetylase Inhibitor (HDACi) Vorinostat in Niemann-Pick Type C1 disease.

Authors:  Kanagaraj Subramanian; Navin Rauniyar; Mathieu Lavalleé-Adam; John R Yates; William E Balch
Journal:  Mol Cell Proteomics       Date:  2017-08-31       Impact factor: 5.911

7.  Quantifying Competition among Mitochondrial Protein Acylation Events Induced by Ethanol Metabolism.

Authors:  Hadi R Ali; Mohammed A Assiri; Peter S Harris; Cole R Michel; Youngho Yun; John O Marentette; Frank K Huynh; David J Orlicky; Colin T Shearn; Laura M Saba; Richard Reisdorph; Nichole Reisdorph; Matthew D Hirschey; Kristofer S Fritz
Journal:  J Proteome Res       Date:  2019-01-31       Impact factor: 4.466

Review 8.  Histone deacetylase inhibitors and transplantation.

Authors:  Ran Tao; Edwin F de Zoeten; Engin Ozkaynak; Liqing Wang; Bin Li; Mark I Greene; Andrew D Wells; Wayne W Hancock
Journal:  Curr Opin Immunol       Date:  2007-08-24       Impact factor: 7.486

9.  Histone deacetylase 3 suppresses Erk phosphorylation and matrix metalloproteinase (Mmp)-13 activity in chondrocytes.

Authors:  Lomeli R Carpio; Elizabeth W Bradley; Jennifer J Westendorf
Journal:  Connect Tissue Res       Date:  2016-09-23       Impact factor: 3.417

10.  A Designed Enzyme Promotes Selective Post-translational Acylation.

Authors:  Pallavi M Gosavi; Megha Jayachandran; Joel J L Rempillo; Oleksii Zozulia; Olga V Makhlynets; Ivan V Korendovych
Journal:  Chembiochem       Date:  2018-06-21       Impact factor: 3.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.